Table 2. GRADE table ASM.
| 6 or 6–12 months compared to 12–24 or 24 months ASM for individuals with SEL NCC Bibliography: [18–21] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CERTAINTY ASSESSMENT | SUMMARY OF FINDINGS | ||||||||||
| № of participants (studies) Follow-up | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall certainty of evidence | Study event rates (%) | Relative effect (95% CI) | Anticipated absolute effects | ||
| With 12–24 or 24 months ASM | With 6 or 6–12 months ASM | Cumulative incidence with 12–24 or 24 months ASM | Cumulative incidence difference with 6 or 6–12 months ASM | ||||||||
| Seizure recurrence in 6 months compared to 12–24 months ASM for individuals with SEL NCC | |||||||||||
| 360 (3 RCTs) | serious a | not serious | serious b | not serious | none | ⨁⨁◯◯ LOW | 21/174 (12.1%) | 29/186 (15.6%) | CIR 1.29 (0.76 to 2.18) | 121 per 1.000 | 35 more per 1.000 (29 fewer to 142 more) |
| Seizure recurrence in 6–12 months compared to 24 months ASM for individuals with SEL NCC | |||||||||||
| 279 (2 RCTs) | serious a | not serious | serious b | not serious | none | ⨁⨁◯◯ LOW | 16/134 (11.9%) | 24/145 (16.6%) | CIR 1.34 (0.76 to 2.51) | 119 per 1.000 | 41 more per 1.000 (29 fewer to 180 more) |
| Seizure recurrence in 6 months compared to 24 months ASM in individuals with SEL NCC, whose cysts had calcified | |||||||||||
| 113 (2 RCTs) | serious a | not serious | not serious | not serious | none | ⨁⨁⨁◯ MODERATE | 13/58 (22.4%) | 24/55 (43.6%) | CIR 2.00 (1.14 to 3.52) | 224 per 1.000 | 224 more per 1.000 (31 more to 565 more) |
CI: Confidence interval; CIR: Cumulative incidence ratio
Explanations:
a. Overall high risk of bias of included studies
b. differences in populations